Basic/Clinical Science Session

Fibroblast Growth Factor 23 and Outcomes: New Answers, New Questions, Including the Jack W. Coburn, MD, Endowed Lectureship

November 07, 2019 | 02:00 PM - 04:00 PM

Location: 145, Walter E. Washington Convention Center

Session Description

Fibroblast growth factor 23 (FGF-23) is a bone-derived hormone suppressing phosphate reabsorption and vitamin D hormone synthesis in the kidney. It is well established that excessive concentrations of intact FGF-23 in the blood lead to phosphate wasting in patients with normal kidney function. Regulators of FGF-23 production include parathyroid hormone (PTH), vitamin D, dietary phosphate, and inflammation. This session discusses new regulatory actions and implications of FGF-23 and treatment options for x-linked hypophosphatemia.

ASN gratefully acknowledges Amgen for support of the Jack W. Coburn, MD, Endowed Lectureship.

Learning Objective(s)

  • Describe the physiological role of FGF-23
  • Describe information on novel regulatory concepts for FGF-23
  • Discuss the treatment of x-linked hypophosphatemia

Learning Pathway(s)

  • Bone and Mineral Metabolism
  • Chronic Kidney Disease


  • Tamara Isakova, MD
  • Carsten A. Wagner, MD